Healthcare Nov 19, 2020 08:05 PM (GMT+8) · EqualOcean
According to the announcement of the new industry, the company's PIVKA - Ⅱ (CLIA) abnormal prothrombin assay kit (chemiluminescence immunoassay) has completed all the procedures of EU access, can paste CE mark into the EU market, and increase the reagent menu of advantageous project category "tumor markers", which will further enhance the comprehensive competitiveness of the company's products.